Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : T/FIF Portfolio -- Ignore unavailable to you. Want to Upgrade?

To: Mike McFarland who wrote (122)	9/30/1998 10:03:00 AM
From: scaram(o)uche	Read Replies (2) \| Respond to of 1073

Getting more efficient? Beat this..... >> how much of that which is functional is devoted to the immune system? << Dunno. >> how much for T cells, and of that how much devoted to the CD4 protein? << Dunno. >> now will they develop a way to manipulate the gene? << Dunno, but they're going to try. Subject relevant to thread...... few realize that CEGE is in the middle of the TKTX/Hoechst efforts to go eye-to-eye with AMGN on epo, and that they will derive royalties from any sales that might derive from the efforts and court battle. They got a milestone payment today. The shares are available at 3 3/8, which is a good ratio to cash, not so good to book. I bought a few shares.